In multiple sclerosis (MS), the fatty sheath that wraps around axons, called myelin, is damaged. However, there are currently no approved treatments for Multiple sclerosis patients that focus specifically on myelin repair, and current treatments only slow disease progression rather than halt it entirely. Drugs that focus on increasing the level of thyroid hormone promote myelin repair, but are unusable due to their extreme side effects. However, a few days ago a paper came out in JCI Insight that utilised a drug called Sob-AM2 to enter into the nervous system and selectively increase the level of thyroid hormone. This resulted in myelin repair and improvements in movement in three mouse models of MS, without side effects. This has huge implications on the future of MS treatment and it has the potential to change how we treat patients living with MS.